Skip to main content

Rare lung & airway condition

MAC lung disease: treatment decisions

Mycobacterium avium complex (MAC) is the commonest NTM lung infection, and the hardest question is often not how to treat but whether and when - balancing slow disease against long, imperfect therapy.

Key points

The essentials at a glance.

What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.

  • 01

    Watchful waiting is legitimate for mild, stable nodular disease; cavities, progression or significant symptoms tip towards treatment.

  • 02

    Standard therapy is a three-drug regimen (macrolide, ethambutol, rifampicin) taken until 12 months after sputum converts to negative.

  • 03

    Three-times-weekly dosing suits milder nodular disease; daily therapy (sometimes with initial injectables) is used for cavitary disease.

  • 04

    Never treat with a macrolide alone - resistance follows and dramatically worsens outcomes.

  • 05

    Amikacin liposome inhalation is an option for refractory disease; adherence, monitoring and re-culturing underpin every decision.

Understanding it

What it is, and what happens next.

In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.

MAC treatment asks a great deal - a year and a half of three antibiotics with visual, hearing and liver checks - for a disease that sometimes smoulders harmlessly for years. The decision framework therefore leans on trajectory: serial CT and cultures showing stability can justify observation, while cavitation, falling weight or advancing scans argue that the infection is winning.

These judgements are best shared with clinicians experienced in NTM: they will confirm the diagnosis meets criteria, choose intermittent or daily regimens by phenotype, protect the macrolide with proper companion drugs, arrange monitoring, and reassess honestly at each milestone - including recognising when refractory disease warrants inhaled amikacin or surgical opinion. In many parts of the UK, routine NHS outpatient referrals for problems like this can take several months, whereas an initial appointment with a private consultant is typically available within around two weeks.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.

Published 2026-09-27 · Next review 2027-09-27

Frequently asked

Common questions about MAC lung disease: treatment decisions.

Quick, plain-English answers to what people ask us most.

  • What is MAC lung disease?

    MAC lung disease is a chronic lung infection caused by Mycobacterium avium complex, a group of environmental bacteria related to tuberculosis, that can cause a slowly progressive lung infection, particularly in people with existing lung conditions or weakened immune systems. Treatment decisions are often complex given the lengthy treatment course required.

  • What causes MAC lung disease?

    It's caused by inhaling Mycobacterium avium complex bacteria, which are common in the environment, particularly in soil and water, though most people exposed don't develop disease. Underlying lung conditions such as bronchiectasis, or a weakened immune system, increase susceptibility to developing infection.

  • What are the symptoms of MAC lung disease?

    Symptoms include a persistent cough, sometimes with sputum production, fatigue, weight loss, and occasionally coughing up blood. Symptoms often develop and progress slowly over months to years, which can make diagnosis challenging.

  • Is MAC lung disease dangerous?

    It can cause progressive lung damage if untreated, though the rate of progression varies considerably between individuals, with some people having a very slow, stable course. Treatment decisions weigh the potential benefits against the significant duration and side effects of the required antibiotic regimen.

  • Is MAC lung disease genetic?

    No, it's caused by environmental bacterial infection rather than being inherited, though certain underlying lung conditions that increase susceptibility, such as some forms of bronchiectasis, can have genetic components. It's not passed on to children through genetics.

  • Can MAC lung disease be cured?

    It can potentially be cured with a prolonged course of combination antibiotics, though treatment typically needs to continue for at least a year, and success rates vary. Some people, particularly with mild, stable disease, may be monitored without immediate treatment if the risks and burdens of treatment outweigh the expected benefit.

  • How are treatment decisions made for MAC lung disease?

    Decisions weigh factors including symptom severity, disease progression on imaging, overall health and ability to tolerate a lengthy antibiotic course, and personal preferences given the significant treatment burden involved. This is often a shared decision between patient and specialist, considering the balance of benefits and downsides carefully.

  • How is MAC lung disease treated?

    Treatment typically involves a combination of several antibiotics taken together for at least twelve months, chosen based on specific testing of the bacteria's sensitivity. Given the length and complexity of treatment, close monitoring for side effects and treatment response is important throughout.

  • Watchful monitoring vs active treatment for MAC lung disease — what's the difference?

    Watchful monitoring, appropriate for milder, stable disease, involves regular imaging and symptom review without starting antibiotics, avoiding the significant burden of prolonged treatment, while active treatment commits to the lengthy multi-drug antibiotic course aimed at achieving cure or significant disease control. This decision is highly individualised based on your specific disease severity and personal circumstances.

  • When should I see a specialist about MAC lung disease treatment decisions, and how quickly can I be seen privately?

    If you've been diagnosed with MAC lung disease, specialist respiratory assessment is important to weigh up the best individualised approach. Private respiratory consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.